Endless Health pairs easy in-home predictive biomarker testing with AI-guided health coaching to catch heart and metabolic disease earlier. The wedge is not a consumer brand but a white-label testing-and-software rail that lets wellness practices, screening partners and pharma programs run at-home diagnostics on Endless's own CLIA-certified lab. That picks-and-shovels posture lets the company earn enterprise contract revenue instead of fighting for direct-to-consumer attention in a crowded at-home-testing market.
By the April 2024 diligence calls the company was doing roughly $1M-$2M of revenue with a credible path to $5M, anchored by named enterprise pull: a 10K-kit order from a heart-health foundation and a Care Access pre-screening pipeline the founder sized at a potential $4M-$5M contract (Internal). The seed closed at $4.5M on a ~$20M post led by Next Coast Ventures, which took a board seat; Antler, Asset Management Ventures and TA Ventures joined, with Reify Health strategic (Internal/Web). StoryHouse invested $200,000 out of Fund I. The deal reached the firm via a Claremont path: Pomona-affiliated founder Cooper Galvin, introduced and mentored through KGI's Ross Grossman and Miles Bird (Internal).
The narrow lipoprotein(a) test-kit segment is ~$488M in 2025 growing at ~8.5% (Web), but Endless plays the far larger and faster-growing at-home / longevity biomarker-testing market spanning cardiovascular, metabolic and Alzheimer's-linked panels (Web). The sharpest tailwind is pharma-created demand: per the diligence notes, Novartis is funding foundations to pre-screen patients for Lp(a)-related therapies, which pulls through exactly the testing volume Endless supplies (Internal). White-label positioning lets the company monetize that demand as infrastructure rather than a consumer brand.
| Player | Positioning | Funding / Stage | Edge vs. them |
|---|---|---|---|
| Endless Health | White-label at-home testing + practice software on an owned CLIA lab | Seed, $4.5M | — |
| Everlywell | D2C at-home heart / lipid kits, CLIA lab, telehealth | Late-stage, well funded | Endless sells infrastructure to practices, not a consumer brand |
| Function Health | Consumer longevity membership, 100+ biomarkers ~$365/yr | Growth-stage | Endless is B2B / enterprise; avoids consumer CAC |
| LetsGetChecked | D2C diabetes & heart tests incl. Lp(a) | Late-stage | Endless owns lab + white-label software stack |
| SiPhox / Superpower | At-home biomarker upstarts, blood-from-arm collection | Early / Seed | Endless has enterprise contract revenue, not just D2C |
Moat: owning a CLIA/CAP-certified lab plus the white-label software layer creates switching costs for practice and screening-partner customers and gives Endless margin control that pure resellers lack (Internal/Web).
Most probable outcome is strategic M&A into a diagnostics or lab consolidator. The sector is actively rolling up: Quest Diagnostics alone made multiple 2024 lab acquisitions ($100M–$1B each), and analysts expect at-home / consumer-lab M&A to accelerate through 2030 on multi-billion-dollar deal volume (Web). Natural acquirers include lab majors (Quest, LabCorp), D2C testing brands (Everlywell), and strategic investor Reify Health. On terms, StoryHouse entered at a ~$20M post; a 2026 raise reported at a ~$50M post already implies a ~2.5x paper markup on the entry (Internal).
Follow-up diligence with Cooper Galvin probing durability of the business and the need to scale quickly while building rapport for a longer relationship.
Is there any cyclical nature to their business? The types of drugs that are hot, and how they cycle, lasts probably 5 years; by the time they aren't hot anymore they need to have built other revenue streams.
Very credible if the partner is actually doing these large numbers; should verify. It will be important that they scale quickly.
We'd like to maximize the benefits and minimize any potential issues; starting to build rapport early so we can maximize how we can help in that relationship with them.
Core diligence call covering the financing stack, the CLIA lab acquisition, the revenue ramp, and enterprise pipeline including Care Access and a foundation kit order.
On the acquisition: they are going to acquire their lab for $300–500K; it is a CLIA- and CAP-certified lab which helps bring things to market. The lab director will take the scientific-director role Cooper has been doing. They can process 50K samples if they rent the space next door.
On the path to $1M–$4M ARR: he will do $1–2M this year and thinks they would hit $5M next year. Care Access already has hundreds of millions to do pre-screens; that contract alone could be $4–5M, but to earn it they would need to do all its Lp(a) testing and a third of its Alzheimer's testing.
On the raise: $4M. He thinks the investments needed are ~$2M over two years, front-loaded into biotech and tech certifications and R&D; ~$2M for scaling and development (40% R&D, the rest capex), scaling to 50K/month capacity.
Financing: Antler Global wants 1–1.5M; two other insiders want at least 300K; Silverton wants 3.5M of the 4M; Next Coast Ventures is on Everlywell's board.
News: a 10K-kit order from the Black Heart Association; Care Access is running bigger screening events and at-home testing, expanded to 200K; Novartis is putting money into foundations to screen these people so there is a market.
Email in which Cooper forwarded the financial model and customer pipeline and laid out the seed terms he was leaning toward accepting.
Cooper forwarded key data from the FAQ including the financial model and pipeline of customers. He asked that the documents stay confidential and proprietary, as they are central to the company's strategy.
He wrote that he was leaning toward accepting the terms received that day from Next Coast Ventures, which would put the company at $20M post, with Next Coast investing $2.5M and taking a board seat, leaving $1.5M for other investors. Of that remainder, he believed Antler would do $0.75M (they wanted $1.5M) and another $0.75M could be good for Reify if it stayed within their target ownership.
Ross Grossman (KGI), who has been coaching and mentoring Cooper Galvin, referenced him in a November 2023 email, noting Cooper's diagnostic/analytics startup was about to sign a significant deal with Amgen and that Miles Bird had made the original connection. The reference is positive on the founder and corroborates early enterprise/pharma pull (Internal, Meeting Notes recZ5TUmmehzKK2Qg).